Thursday, April 24, 2014

PhRMA Blasts Medicaid Rx Rebate Proposal, Discounts Reports Of GOP Interest

Brand-drug makers are pushing back on a debt-limit proposal to extend Part D rebates to dually eligible beneficiaries, citing industry-funded research findings that biopharmaceutical industry revenue cuts of this magnitude would result in the loss of more than 200,000 high-paying jobs.


You've followed a link to an article or document on InsideHealthPolicy.com.
There are three ways you can access this content.

Subscriber Login

If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:

Take A Trial Subscription

If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.

Sign up for a trial subscription.

Buy This Article

You can also buy this and other individual InsideHealthPolicy.com articles by going to the InsideHealthPolicy.com NewsStand. Articles are $5 apiece. We'll even give you your first download free.

Here's a direct link to this article on the NewsStand.